Department of Psychology, Maynooth University, National University of Ireland, Maynooth, Ireland.
Department of Psychiatry, Laboratory of Molecular Psychiatry, School of Medicine, University of Rostock, Rostock, Germany.
Neuropsychopharmacology. 2019 Jun;44(7):1198-1206. doi: 10.1038/s41386-019-0327-6. Epub 2019 Feb 6.
Attention deficit hyperactivity disorder (ADHD) is a common neuropsychiatric condition that has been strongly associated with changes in sleep and circadian rhythms. Circadian rhythms are near 24-h cycles that are primarily generated by an endogenous circadian timekeeping system, encoded at the molecular level by a panel of clock genes. Stimulant and non-stimulant medication used in the management of ADHD has been shown to potentially impact on circadian processes and their behavioral outputs. In the current study, we have analyzed circadian rhythms in daily activity and sleep, and the circadian gene expression in a cohort of healthy controls (N = 22), ADHD participants not using ADHD-medication (N = 17), and participants with ADHD and current use of ADHD medication (N = 17). Rhythms of sleep/wake behavior were assessed via wrist-worn actigraphy, whilst rhythms of circadian gene expression were assessed ex-vivo in primary human-derived dermal fibroblast cultures. Behavioral data indicate that patients with ADHD using ADHD-medication have lower relative amplitudes of diurnal activity rhythms, lower sleep efficiency, more nocturnal activity but not more nocturnal wakenings than both controls and ADHD participants without medication. At the molecular level, there were alterations in the expression of PER2 and CRY1 between ADHD individuals with no medication compared to medicated ADHD patients or controls, whilst CLOCK expression was altered in patients with ADHD and current medication. Analysis of fibroblasts transfected with a BMAL1:luc reporter showed changes in the timing of the peak expression across the three groups. Taken together, these data support the contention that both ADHD and medication status impact on circadian processes.
注意缺陷多动障碍(ADHD)是一种常见的神经精神疾病,与睡眠和昼夜节律变化密切相关。昼夜节律是接近 24 小时的周期,主要由内源性昼夜节律计时系统产生,在分子水平上由一组时钟基因编码。用于 ADHD 管理的兴奋剂和非兴奋剂药物已被证明可能会影响昼夜节律过程及其行为输出。在目前的研究中,我们分析了健康对照组(N=22)、未使用 ADHD 药物的 ADHD 参与者(N=17)和正在使用 ADHD 药物的 ADHD 参与者(N=17)的日常活动和睡眠昼夜节律以及昼夜节律基因表达。通过腕戴活动记录仪评估睡眠/觉醒行为节律,同时通过体外原代人源性皮肤成纤维细胞培养评估昼夜节律基因表达的节律。行为数据表明,使用 ADHD 药物的 ADHD 患者的日间活动节律相对振幅较低,睡眠效率较低,夜间活动较多,但夜间醒来次数不比无药物治疗的对照组和 ADHD 患者多。在分子水平上,与未用药的 ADHD 个体相比,未用药的 ADHD 个体中 PER2 和 CRY1 的表达发生改变,而 CLOCK 的表达在正在服用药物的 ADHD 患者中发生改变。用 BMAL1:luc 报告基因转染成纤维细胞的分析显示,三组的峰值表达时间发生了变化。综上所述,这些数据支持 ADHD 和药物状态都会影响昼夜节律过程的观点。